Cagrilintide
Long-Acting Amylin Receptor Agonist
Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk for weight management and metabolic health. It mimics the action of naturally occurring amylin hormone, which is co-secreted with insulin from pancreatic beta cells. Currently in Phase 3 clinical trials as part of CagriSema (combination with semaglutide), cagrilintide provides enhanced appetite suppression and gastric emptying control through amylin pathway activation.
Complete Dosing Guide
Who Should Not Take Cagrilintide & Safety Tips
Do Not Take If:
- You have a personal or family history of medullary thyroid carcinoma
- You have Multiple Endocrine Neoplasia syndrome type 2
- You're allergic to cagrilintide or any components
- You have severe gastroparesis
Use Carefully If:
- You have a history of pancreatitis
- You have gallbladder disease
- You have severe gastrointestinal disease
- You're taking other medications that slow gastric emptying
Who Should Not Take Cagrilintide & Safety Tips
Do Not Take If:
- You have a personal or family history of medullary thyroid carcinoma
- You have Multiple Endocrine Neoplasia syndrome type 2
- You're allergic to cagrilintide or any components
- You have severe gastroparesis
Use Carefully If:
- You have a history of pancreatitis
- You have gallbladder disease
- You have severe gastrointestinal disease
- You're taking other medications that slow gastric emptying
Medical Disclaimer
This information is for educational purposes only. Cagrilintide is currently in Phase 3 clinical trials and is not yet approved for commercial use. It requires prescription and medical supervision when available. This content does not constitute medical advice and should not replace consultation with qualified healthcare professionals. Participation in clinical trials may be available through clinicaltrials.gov.